Phospho erk 1 2 t202 y204

Manufactured by Abcam

Sourced in United States

Phospho-ERK 1/2 (T202 + Y204) is an antibody that detects endogenous levels of ERK1 and ERK2 proteins only when dually phosphorylated at Thr202/Tyr204 (ERK1) or Thr185/Tyr187 (ERK2). This antibody can be used in various applications such as immunoblotting, immunoprecipitation, and immunohistochemistry.

Automatically generated - may contain errors

Lab products found in correlation

P38 mapk, by Abcam (1 mentions) Parp1, by Abcam (1 mentions) Phospho p38mapk t180 y182, by Abcam (1 mentions) Caspase 8, by Abcam (1 mentions) Gadd45a, by Abcam (1 mentions) Bcl2 associated x (bax), by Cell Signaling Technology (1 mentions) Bcl 2, by Abcam (1 mentions) Erk1 2, by Abcam (1 mentions) Phospho akt t308, by Abcam (1 mentions) Phospho akt s473, by Abcam (1 mentions) Pierce bca protein assay, by Thermo Fisher Scientific (1 mentions)

Spelling variants of this product

Phospho-ERK (15 citations)

2 protocols using phospho erk 1 2 t202 y204

Comprehensive Antibody Analysis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA) and used as follows: BAX (no. ab32503, diluted: 1:1000), BCL-2 (no. ab32124, diluted: 1:1000), CASPASE8 (no. ab32397, diluted: 1:1000), PARP1 (no. ab32138, diluted: 1:1000), GADD45A (no. ab203090, diluted: 1:500), p38/MAPK (no. ab170099, diluted:1:1000), phospho-p38MAPK (T180 + Y182) (no. ab195049, diluted: 1:1000), ERK1/2 (no. ab184699, diluted: 1:1000), phospho-ERK 1/2 (T202 + Y204) (no. ab223500, diluted: 1:1000) were purchased from Abcam (Cambridge, USA). Cleaved-caspase 8 (no. 8592, diluted: 1:1000), GAPDH (no. 5174), CDC2 (no. 28439, diluted: 1:1000), CYCLINB1 (no. 4138, diluted: 1:1000), PLK1 (no. 4535, diluted: 1:1000), MMP-1 (no. ab137332, diluted: 1:1000), MMP-9 (no. 13667s, diluted: 1:1000), VEGF-1 (no. 2893s, diluted: 1:1000). Anti-rabbit and anti-mouse LgG (H + L) (Dylight (TM) 800 4×PEG Conjugate) secondary antibodies used in this study were purchased from Cell Signaling Technology and used at a 1:30000 dilution in the experiments.

Wang M., Zeng X., Li S., Sun Z., Yu J., Chen C., Shen X., Pan W, & Luo H. (2019). A Novel Tanshinone Analog Exerts Anti-Cancer Effects in Prostate Cancer by Inducing Cell Apoptosis, Arresting Cell Cycle at G2 Phase and Blocking Metastatic Ability. International Journal of Molecular Sciences, 20(18), 4459.

+ Open protocol

+ Expand

Cell Signaling Protein Profiling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were treated with drugs in 6-well plates for 5–8 hours or as indicated. Cell protein lysates were prepared in ice-cold RIPA lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 2mM EDTA, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, containing Roche protease inhibitors and Calbiochem phosphatase inhibitor cocktail set I and II). Debris was removed by centrifugation in a microfuge at max speed for 10 min at 4 C. Protein concentration in clarified lysate was determined by Pierce BCA protein assay (Thermo Fisher Scientific). Ten micrograms of protein were used to perform analysis by SDS-PAGE, electro-transfer and immunoblotting with specific antibodies. The following antibodies were used: from Cell Signaling Technology (all at 1:1000 dilution): phospho-FRS2 Y196 (3864S), SHP2 (3397S), phospho-MEK1/2 S217/221 (9154S), MEK1/2 (4694S), phospho-ERK1/2 T202/Y204 (9106S), ERK1/2 (4695S), phospho-AKT T308 (13038S), phospho-AKT S473 (4060S), AKT (9272S), FGFR1 (9740S); from Abcam (1:5000 dilution): FRS2 (ab183492), phospho-SHP2 Y542 (ab62322); from Sigma (1:20,000 dilution): b-actin (A5316).

Goyal L., Shi L., Liu L.Y., de la Cruz F.F., Lennerz J.K., Raghavan S., Leschiner I., Elagina L., Siravegna G., Ng R.W., Vu P., Patra K.C., Saha S.K., Uppot R.N., Arellano R., Reyes S., Sagara T., Otsuki S., Nadres B., Shahzade H.A., Dey-Guha I., Fetter I.J., Baiev I., Van Seventer E.E., Murphy J.E., Ferrone C.R., Tanabe K.K., Deshpande V., Harding J.J., Yaeger R., Kelley R.K., Bardelli A., Iafrate A.J., Hahn W.C., Benes C.H., Ting D.T., Hirai H., Getz G., Juric D., Zhu A.X., Corcoran R.B, & Bardeesy N. (2019). TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer discovery, 9(8), 1064-1079.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!